论文部分内容阅读
对不适合常规清髓性异基因造血干细胞移植(HSCT)者,非清髓性异基因HSCT逐渐成为一种治疗选择。但该方法能否降低移植相关感染率,尚不清楚。本文旨在配对比较分析各种方法移植后巨细胞病毒(CMV)感染率。 方法 1997年1月至2000年4月血液系统恶性肿瘤患者56例,进行非清髓性HSCT(第0天给予TBI 2 Gy照射;移植后给予环孢素);其中有18例于第-4天至第-2天接受氟达拉宾 30 mg·m~(-2)·d~(-1)预处理。多数供者为HLA相合或相关。每1例非清髓性HSCT患者配对2例同期常规清髓性HSCT患者作为对
Non-myeloablative allogeneic HSCT has gradually become a treatment option for those who are not suitable for conventional myeloablative allogeneic hematopoietic stem cell transplantation (HSCT). However, whether this method can reduce the infection rate associated with transplantation is unclear. This article aims to paired comparison analysis of various methods of cytomegalovirus (CMV) infection rate after transplantation. Methods From January 1997 to April 2000, 56 patients with hematologic malignancies underwent non-myeloablative HSCT (2 Gy of TBI on day 0; cyclosporine on day 0 after transplantation). Among them, 18 Day 2- received fludarabine 30 mg · m -2 d -1. Most donors are HLA matched or related. Two matched primary myeloablative HSCT patients were matched for each one non-myeloablative HSCT patient